Ferryx key facts
as of Nov 2026- Developer of live biotherapeutics designed to treat inflammatory conditions in humans and animals.
- Ferryx is valued at approximately $3.9M as of Nov 2026 (last reported valuation).
- It has raised $960K; the latest was Seed Round ($200K) in Apr 2026.
- Notable investors include Innovate UK, EIT Food, University of Bristol, Deepbridge Capital, Evenlode Foundation — 8 tracked in total.
- Status: Privately Held (backing).
Ferryx's last reported valuation, Apr 2026. Nothing priced has surfaced since.
Ferryx funding rounds
No funding rounds for Ferryx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ferryx valuation
Ferryx's last reported valuation was $3.9 million in Apr 2026. No priced round, secondary trade or fund mark has surfaced since.
Ferryx investors
8 investors are on record for Ferryx, including Innovate UK, EIT Food, University of Bristol and Deepbridge Capital.
About Ferryx
Developer of live biotherapeutics designed to treat inflammatory conditions in humans and animals. The company develops safe and effective bacterial products that prevent and treat gastrointestinal inflammation and conditions, including inflammatory bowel disease and irritable bowel syndrome, enabling the medical community and patients with safe and natural alternatives to traditional medications that have negative side effects.
- Sector
- Healthcare
- HQ
- Bristol, United Kingdom
- Founded
- 2019
- Employees
- 5
- Website
- ferryx.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.